A Phase 2 Open-label Study Evaluating the Efficacy and Safety of Luveltamab tazevibulin (STRO-002) in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (Included Fallopian Tube or Primary Peritoneal Cancers) expressing Folate Receptor alpha (FOLR1)
Brief description of study
The objectives of this study are to evaluate the efficacy of luveltamab tazevibulin in subjects with relapsed platinum-resistant epithelial ovarian cancer expressing FOLR1. In addition to this main objective, the study will also assess the additional efficacy outcome measures, as well as the safety and tolerability of luveltamab tazevibulin in subjects with relapsed platinum-resistant epithelial ovarian cancer expressing FOLR1.
Detailed description of study
This study is currently Enrolling by Invitation at Lancaster General Hospital - ABBCI.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
epithelial ovarian cancer expressing FOLR1
-
Age: 18 Years
-
Gender: Female
Inclusion Criteria: (this is not a complete list)
- 18 years of age or older.
- High grade serous epithelial ovarian cancer, fallopian tube or primary peritoneal cancer with pathology report documentation of tumor type.
- Positive FOLR1 expression per lab tasting
Exclusion Criteria: (this is not a complete list)
- Low-grade (Grade 1) ovarian carcinoma
- Clear cell, mucinous, endometrioid, sarcomatous, and mixed histology ovarian carcinomas.
- Greater than 3 lines of prior treatment
Updated on
04 Apr 2024.
Study ID: STRO-002-GM3
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
